• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The Symplicity HTN-2 trial: Renal denervation in treatment-resistant hypertension [Classics Series]

byAndrew Cheung, MD MBA
November 22, 2013
in General Medicine Classics, Surgery Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Renal denervation significantly reduces blood pressure in patients suffering from treatment-resistant hypertension

2. Renal denervation was not associated with a significantly higher rate adverse events in comparison to control

Original Date of Publication: December 4, 2010

Study Rundown: Approximately half of hypertensive patients do not experience a reduction in blood pressure despite treatment with pharmaceutical agents and/or lifestyle changes. Efferent sympathetic outflow from kidneys can stimulate renin release and increased tubular sodium reabsorption, thereby increasing blood pressure. Afferent sympathetic outflow from kidneys can influence central sympathetic signals and contribute to neurogenic hypertension. Previous non-randomized trials suggest that renal denervation can successfully ameliorate treatment-refractory hypertension. The Symplicity HTN-2 trial was the first study to randomize patients with treatment-resistant hypertension (i.e., persistent hypertension despite compliance with three or more antihypertensive drugs) to receive renal denervation or not. Results showed that renal denervation can significantly lower blood pressure in these treatment-refractory patients. Treatment with renal denervation was not linked with significantly higher rates of adverse events. There was no major injury to the renal arteries or evidence of worsening renal function associated with the denervation procedure.

Limitations of the study include the low percentage of patients (17%) in both experimental groups that were reported to having used an aldosterone antagonist prior to the study. This raises the concern that the participants’ hypertension may not have been resistant to all available effective drug therapies. Additionally, study participants were only monitored for 6 months, thus the long-term effects of renal denervation were not assessed. It should be noted that more recent studies have shown similar results extended to 24 months.

In summary, the results of the Symplicity HTN-2 trial suggest that catheter-based renal denervation can be safely and effectively used to reduce blood pressure in treatment-refractory hypertensive patients.

RELATED REPORTS

Treating mild chronic hypertension associated with better pregnancy outcome

Radiofrequency renal denervation produces long-lasting reductions in blood pressure

2 Minute Medicine Rewind February 14, 2022

Please click to read study in The Lancet

In-Depth [randomized, controlled study]: Published in 2010 in The Lancet, the Symplicity HTN-2 trial was a randomized, controlled trial involving 106 participants from Europe, Australia, and New Zealand. Eligible patients were between the ages of 18 and 85 with a systolic blood pressure (BP) of at least 160 mmHg, despite compliance with at least three hypertensive drugs. Exclusion criteria included a GFR of less than 45 mL/min/1.73 m2, type 1 diabetes mellitus, valvular heart disease, and pregnancy. Renal denervation was performed using the Symplicity catheter to apply radiofrequency treatments along both renal arteries. Changes in the baseline doses of anti-hypertensive drugs were not permitted during the trial. Patients’ BP was measured at 1, 3, and 6 months using office-based and home-based blood pressure machines. Adverse effects were assessed by measuring serum creatinine concentration, cystatin C concentration, and urine albumin-to-creatinine ratio. Kidneys in the denervation group were also imaged by ultrasound. Results based on office-based BP measurements showed that renal denervation resulted in a significant BP decrease of 32/12 mmHg (p<0.0001), while the control group experienced no significant change. At 6 months, office-based BP of patients in the denervation group was significantly lower than the control group (between-group difference of 33/11 mmHg, p<0.0001). Home-based BP was also significantly lower in the denervation group (between-group difference of 22/12 mmHg, p<0.001). There was no difference in estimated GFR, serum creatinine, and cystatin C levels between the two groups.

By Evan Chen and Andrew Cheung, M.D.

©2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: denervationhypertension
Previous Post

Stem cell enrichment of fat grafts ineffective in breast augmentation

Next Post

Pediatric appendicitis outcomes in Canada not superior to US

RelatedReports

Prenatal antidepressant exposure may increase risk of poor motor development
Cardiology

Treating mild chronic hypertension associated with better pregnancy outcome

May 13, 2022
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Cardiology

Radiofrequency renal denervation produces long-lasting reductions in blood pressure

April 20, 2022
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Weekly Rewinds

2 Minute Medicine Rewind February 14, 2022

February 14, 2022
Cognitive behavioral therapy effective for insomnia with medical or psychiatric comorbidities
Cardiology

Moderate caffeine intake may not be associated with cardiometabolic pregnancy complications

December 31, 2021
Next Post
Pediatric appendicitis outcomes in Canada not superior to US

Pediatric appendicitis outcomes in Canada not superior to US

Remote ischemic preconditioning reduced myocardial injury in CABG patients

Use of cardiac stem cell factors linked with positive coronary bypass outcome

Antepartum and intrapartum events both linked to neonatal HIE

Phthalate exposure during pregnancy associated with preterm birth

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind May 22nd, 2022
  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.